Suggesting a Deadline in the Invitation Letter to FIT Colorectal Cancer Screening Results in More Timely FIT Return
Findings from the TEMPO study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1627 results
EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence
New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer
FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma
Evidence for efficacy is based on the results from the ECHELON-3 study
Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens in Patients with Gastro-Oesophageal Adenocarcinoma
Biomarker analyses from the CheckMate 649 study
Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy
Findings from the MANIFEST-2 study
No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer
Findings from the TROPiCS-04 study
EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment for HER2-ultralow Breast Cancer
New indication concerns the management of adult patients with unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer
FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection
Evidence for efficacy is based on the results from the ReNeu study
Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients
Findings from a population-based study
Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival Benefits Compared to Those Included in RCTs
Findings from machine learning-based and population-level electronic health record data-based emulation of landmark phase III randomised clinical trials in oncology
Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC
Findings from the Beamion LUNG-1 study
EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC
The combination is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma